药品注册申请号:200626
申请类型:ANDA (仿制药申请)
申请人:CIPLA
申请人全名:CIPLA LTD
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 100MG BASE No No AB 2018/08/09 2018/08/09 Discontinued
002 ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE No No AB 2018/08/09 Discontinued
003 ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE No No AB 2018/08/09 Discontinued
004 ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE No No AB 2018/08/09 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/11/22 SUPPL-5(补充) Approval Labeling STANDARD
2023/08/07 SUPPL-3(补充) Approval Labeling STANDARD
2018/08/09 ORIG-1(原始申请) Approval Not Applicable
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:ATAZANAVIR SULFATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 100MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
091673 001 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 100MG BASE Prescription No No AB 2014/04/22 TEVA PHARMS USA
204806 001 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 100MG BASE Prescription No No AB 2018/06/25 AUROBINDO PHARMA
200626 001 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 100MG BASE Discontinued No No AB 2018/08/09 CIPLA
活性成分:ATAZANAVIR SULFATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 150MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
091673 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 2014/04/22 TEVA PHARMS USA
204806 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 2018/06/25 AUROBINDO PHARMA
200626 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Discontinued No No AB 2018/08/09 CIPLA
209717 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Discontinued No No AB 2020/06/01 AMNEAL
212579 001 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 2021/04/30 LAURUS
212278 001 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 150MG BASE Prescription No No AB 2022/02/02 HETERO LABS LTD III
活性成分:ATAZANAVIR SULFATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 200MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021567 003 NDA REYATAZ ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Prescription Yes No AB 2003/06/20 BRISTOL MYERS SQUIBB
091673 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Prescription No No AB 2014/04/22 TEVA PHARMS USA
204806 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Prescription No No AB 2018/06/25 AUROBINDO PHARMA
200626 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Discontinued No No AB 2018/08/09 CIPLA
209717 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Discontinued No No AB 2020/06/01 AMNEAL
212579 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Prescription No No AB 2021/04/30 LAURUS
212278 002 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 200MG BASE Prescription No No AB 2022/02/02 HETERO LABS LTD III
活性成分:ATAZANAVIR SULFATE 剂型/给药途径:CAPSULE;ORAL 规格:EQ 300MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021567 004 NDA REYATAZ ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Prescription Yes Yes AB 2006/10/16 BRISTOL MYERS SQUIBB
091673 004 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Prescription No No AB 2014/04/22 TEVA PHARMS USA
204806 004 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Prescription No No AB 2018/06/25 AUROBINDO PHARMA
200626 004 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Discontinued No No AB 2018/08/09 CIPLA
209717 004 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Discontinued No No AB 2020/06/01 AMNEAL
212579 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Prescription No No AB 2021/04/30 LAURUS
212278 003 ANDA ATAZANAVIR SULFATE ATAZANAVIR SULFATE CAPSULE;ORAL EQ 300MG BASE Prescription No No AB 2022/02/02 HETERO LABS LTD III
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database